Provided herein are compounds according to Formula (I)
or a pharmaceutically acceptable salt thereof, wherein R
1
, R
2
, R
3
, R
5
, and R
7
are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
[EN] CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4<br/>[FR] HYDROPYRROLES SUBSTITUÉS CONDENSÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR MUSCARINIQUE M4 DE L'ACÉTYLCHOLINE
申请人:UNIV VANDERBILT
公开号:WO2021216951A1
公开(公告)日:2021-10-28
Disclosed herein are substituted hexahydro-l//-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
本文披露了一种替代的六氢-1H-环戊[ c ]吡咯化合物,可能作为肌碱乙酰胆碱受体M4(mAChR M4)的拮抗剂有用。本文还披露了制备这些化合物的方法、包含这些化合物的药物组合物以及使用这些化合物和组合物治疗疾病的方法。
[EN] TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS<br/>[FR] HÉTÉROCYCLES TRICYCLIQUES EN TANT QU'INHIBITEURS DE FGFR
申请人:INCYTE CORP
公开号:WO2022261160A1
公开(公告)日:2022-12-15
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
[EN] TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS<br/>[FR] HÉTÉROCYCLES TRICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE FGFR
申请人:INCYTE CORP
公开号:WO2022261159A1
公开(公告)日:2022-12-15
The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
[EN] 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS<br/>[FR] DÉRIVÉS DE 2-AZASPIRO[3,4] OCTANE UTILISÉS EN TANT QU'AGONISTES DE M4
申请人:NOVARTIS AG
公开号:WO2021070090A1
公开(公告)日:2021-04-15
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.